SG11201910183SA - C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof - Google Patents
C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereofInfo
- Publication number
- SG11201910183SA SG11201910183SA SG11201910183SA SG11201910183SA SG 11201910183S A SG11201910183S A SG 11201910183SA SG 11201910183S A SG11201910183S A SG 11201910183SA SG 11201910183S A SG11201910183S A SG 11201910183SA
- Authority
- SG
- Singapore
- Prior art keywords
- helsingin
- yliopisto
- fragment
- sequence
- international
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT onion ono o ioo lII 1111111 ow (10) International Publication Number WO 2018/202957 Al (51) International Patent Classification: C07K 14/475 (2006.01) A61K 38/18 (2006.01) (21) International Application Number: PCT/FI2018/050332 (22) International Filing Date: 04 May 2018 (04.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 20175392 04 May 2017 (04.05.2017) FI (71) Applicant: HELSINGIN YLIOPISTO [FI/FI]; Fabi- aninkatu 33, 00014 Helsingin yliopisto (FI). (72) Inventors: SAARMA, Mart; c/o Helsingin yliopis- to, Fabianinkatu 33, 00014 Helsingin yliopisto (FI). AIRAVAARA, Mikko; c/o Helsingin yliopisto, Fabi- aninkatu 33, 00014 Helsingin yliopisto (FI). VOUTILAI- NEN, Merja; c/o Helsingin yliopisto, Fabianinkatu 33, 00014 Helsingin yliopisto (FI). YU, Li Ying; c/o Helsingin yliopisto, Fabianinkatu 33, 00014 Helsingin yliopisto (FI). LINDAHL, Maria; c/o Helsingin yliopisto, Fabianinkatu 33, 00014 Helsingin yliopisto (FI). (74) Agent: SEPPO LAINE OY; Itamerenkatu 3 A, 00180 Helsinki (FI). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 • (54) Title: C-TERMINAL CDNF AND MANF FRAGMENTS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USES THEREOF c7 , (57) : The present invention provides a C-terminal CDNF fragment sequence or a sequence which has at least 90 % homology to ei said sequence. The C-terminal CDNF fragment protects ER stressed neurons, motoneurons and dopaminergic neurons and the fragment is capable of penetrating neuronal cell membrane as well as the blood-brain-barrier. The present invention further provides said fragment ▪ and pharmaceutical compositions comprising said fragment for use in treatments of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders. The present invention is also providing a C-terminal MANF fragment 1-1 sequence or a sequence which has at least 90 % homology to the said sequence and pharmaceutical compositions comprising said MANF fragment for use in the treatment of degenerative diseases and disorders including central nervous system diseases, diabetes 0 and retinal disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20175392 | 2017-05-04 | ||
PCT/FI2018/050332 WO2018202957A1 (en) | 2017-05-04 | 2018-05-04 | C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201910183SA true SG11201910183SA (en) | 2019-11-28 |
Family
ID=62218004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201910183S SG11201910183SA (en) | 2017-05-04 | 2018-05-04 | C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200071372A1 (en) |
EP (1) | EP3619227A1 (en) |
JP (1) | JP7384672B2 (en) |
KR (1) | KR20200003889A (en) |
CN (1) | CN110831960A (en) |
AU (1) | AU2018263087B2 (en) |
BR (1) | BR112019023116A2 (en) |
CA (1) | CA3062241A1 (en) |
MX (1) | MX2019013157A (en) |
RU (1) | RU2019136495A (en) |
SG (1) | SG11201910183SA (en) |
WO (1) | WO2018202957A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2020131433A (en) * | 2018-03-29 | 2022-05-04 | Хельсингин Илиописто | CDNF C-TERMINAL FRAGMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE FRAGMENTS AND USES OF THESE FRAGMENTS AND COMPOSITIONS |
EP3838345A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Macrocyclic peptides |
EP3838912A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Retro-inverso peptides |
WO2021160938A1 (en) | 2020-02-13 | 2021-08-19 | Herantis Pharma Oyj | Systemic administration of a pharmaceutical composition comprising cdnf or manf polypeptide for use in the treatment of reperfusion injury |
CN117018231A (en) * | 2023-08-16 | 2023-11-10 | 科辉智药(深圳)新药研究中心有限公司 | Gene therapy for treatment of neuropathy and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP1373314A2 (en) * | 2001-03-30 | 2004-01-02 | Geneprot, Inc. | Human arginine-rich protein-related compositions |
JP5236488B2 (en) | 2005-12-14 | 2013-07-17 | ハーモ ファーマ エルテーデー. | Novel neurotrophic factor protein and uses thereof |
FI20080326A0 (en) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotrophic factor MANF and its uses |
FI20115870A0 (en) * | 2011-09-05 | 2011-09-05 | Urmas Arumaee | Neuroprotective cell penetrating peptides |
WO2014191630A2 (en) | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
WO2015149005A1 (en) * | 2014-03-28 | 2015-10-01 | Buck Institute For Research On Aging | Methods and compositions for modulating the immune system |
WO2016057579A1 (en) | 2014-10-06 | 2016-04-14 | Amarantus Bioscience Holdings, Inc. | Methods and compositions for treating retinal disorders |
-
2018
- 2018-05-04 BR BR112019023116-1A patent/BR112019023116A2/en unknown
- 2018-05-04 US US16/610,532 patent/US20200071372A1/en active Pending
- 2018-05-04 KR KR1020197035908A patent/KR20200003889A/en unknown
- 2018-05-04 WO PCT/FI2018/050332 patent/WO2018202957A1/en unknown
- 2018-05-04 MX MX2019013157A patent/MX2019013157A/en unknown
- 2018-05-04 AU AU2018263087A patent/AU2018263087B2/en not_active Ceased
- 2018-05-04 RU RU2019136495A patent/RU2019136495A/en unknown
- 2018-05-04 JP JP2019560290A patent/JP7384672B2/en active Active
- 2018-05-04 EP EP18726203.5A patent/EP3619227A1/en active Pending
- 2018-05-04 CA CA3062241A patent/CA3062241A1/en active Pending
- 2018-05-04 CN CN201880044874.3A patent/CN110831960A/en active Pending
- 2018-05-04 SG SG11201910183S patent/SG11201910183SA/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018202957A1 (en) | 2018-11-08 |
JP7384672B2 (en) | 2023-11-21 |
CA3062241A1 (en) | 2018-11-08 |
JP2020518261A (en) | 2020-06-25 |
US20200071372A1 (en) | 2020-03-05 |
MX2019013157A (en) | 2020-08-03 |
RU2019136495A (en) | 2021-06-04 |
BR112019023116A2 (en) | 2020-07-28 |
AU2018263087B2 (en) | 2021-12-16 |
AU2018263087A1 (en) | 2019-11-28 |
KR20200003889A (en) | 2020-01-10 |
CN110831960A (en) | 2020-02-21 |
EP3619227A1 (en) | 2020-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201910183SA (en) | C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof |